ghanfit
Thursday, February 24, 2011
FDA to Consider Relabeling Tamoxifen for 2D6 Response in Fall Meeting; Dx Shops May Benefit | Pharmacogenomics Reporter | DxPGx | GenomeWeb
FDA to Consider Relabeling Tamoxifen for 2D6 Response in Fall Meeting; Dx Shops May Benefit Pharmacogenomics Reporter DxPGx GenomeWeb
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment